India's Lupin hauled up by U.S. FDA for lapses at Goa plant

Mumbai-based Lupin Pharmaceuticals has been hauled up by the U.S. FDA on a manufacturing operation, this time at its Goa plant for failure to meet 9 areas of operating standards. 

 
Lupin's Nilesh Gupta  

The warning comes in the same month Lupin completed a purchase of privately held U.S.-based GAVIS Pharmaceuticals to expand its manufacturing footprint in the U.S.

The inspection of the Goa plant happened last week, Lupin said in a notice to the Bombay Stock Exchange, and the company is working up a reply.

"We wish to state that the U.S. FDA inspected company's Goa facility last week and cited nine observations," Lupin said in the stock exchange note.

"We are in midst of putting together a response to address the FDA's observations."

In February, Lupin Managing Director Nilesh Gupta told the Business Standard newspaper that the company's expansion plans include a deeper foray into Japan with the addition of a plant there and another plant in Goa, India, to work directly with the Japanese market.

In 2011 Lupin made an acquisition in Japan, buying Tokyo-based I'rom Pharmaceutical. In 2007 it bought Kyowa Pharmaceutical Industry.

Lupin's current Goa plant, the Economic Times said, supplies over 100 products to various regulated markets.

- here's the story from the Economic Times
- and a stock exchange notice from Lupin

Suggested Articles

New legal complaints focus on eight Sanofi executives, most of them with local management titles, and 15 managers at distributor Zuellig Pharma.

A self-proclaimed former employee at Novartis’ Beijing office accused the Swiss drugmaker of expensing fake academic events to offer kickbacks to doctors.

A decree includes tax incentives for certain generic drugmakers and uniform insurance standards that apply to both branded drugs and generics.